Dr Rejman noted that "it appears that the Department of Health was encouraging the use of Interferon, where it was appropriate, but accepting that the final decision rested with the purchasers."
Chronology Information
Date:
Chapter/issue
Access to Treatment
Key Person(s)
Dr Andrzej Rejman